Follicular lymphoma presenting with monoclonal IgM And MYD88 Mutation: A case report and review of the literature

2Citations
Citations of this article
5Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

MYD88 mutation has been reported in various lymphomas, specifically in lymphoplasmacytic lymphoma. Yet, the mutation has not been reported in primary follicular lymphoma. Here, we present a 62-year-old male with follicular lymphoma who had an MYD88 L265P somatic mutation and monoclonal IgM gammopathy. He received four cycles of R-CHOP immunochemotherapy. Interim PET/CT evaluation indicated a state of stable disease (SD). Neither did serum IgM remarkably drop. He was then given a bortezomibcontained regimen which significantly reduced the level of serum IgM. To the best of our knowledge, this is the first report of follicular lymphoma with monoclonal IgM and MYD88 L265P mutation. The present case indicated bortezomib may benefit these patients.

Cite

CITATION STYLE

APA

Xu, L., Ding, X., Ying, L., Zhang, X., & Lu, N. (2019). Follicular lymphoma presenting with monoclonal IgM And MYD88 Mutation: A case report and review of the literature. OncoTargets and Therapy, 12, 7833–7842. https://doi.org/10.2147/OTT.S211436

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free